The goal of this study is to evaluate the change in pain scores among patients with chemotherapy-induced peripheral neuropathy after receiving treatment with repetitive transcranial magnetic stimulation (rTMS).
Female subjects aged ≥ 18 years.
Histologically confirmed breast or gynecologic cancer.
Platinum-based drugs
Taxanes
Evidence of recurrent breast or gynecologic cancer at the time of enrollment.
Current or planned treatment with chemotherapy.
History of seizure, epilepsy, or other conditions that would, in the opinion of the investigator, negatively impact the patient's safety or ability to participate in the study.
Presence of neuropathic pain unrelated to systemic cancer therapy, including but not limited to: painful diabetic neuropathy, HIV-induced neuropathy, neuropathic pain from radiation therapy and underlying cancer/other medical conditions.